Larimar Therapeutics Inc
larimartx.comLarimar Therapeutics (NASDAQ: LRMR) is a clinical-stage biopharmaceutical company developing treatments for rare diseases. The company has no approved products and generates no product revenue, operating entirely on capital raises to fund drug development. Its lead program is nomlabofusp, a product candidate requiring FDA approval before any commercial sales can occur. As of the 10-K filed March 19, 2026 (fiscal year ended December 31, 2025), Larimar reported an accumulated deficit and continued net losses, funded through equity issuances including a sales agreement with Guggenheim Securities and an exchange of common stock for Series A preferred stock completed in December 2025 and January 2026. The company has no disclosed product revenue, no commercial partnerships generating royalties, and no manufacturing operations of its own. Research and development expense accruals represent a material portion of its cost structure, audited by PricewaterhouseCoopers LLP.
Products & Services
Nomlabofusp, a clinical-stage product candidate targeting a rare disease indication, pending FDA approval as of the 10-K filed March 19, 2026. No approved or commercialized products disclosed in the filing.
Revenue Model
No product revenue as of FY2025. The company funds operations through equity capital raises, including at-the-market offerings under a sales agreement with Guggenheim Securities dated May 9, 2024.
Customers & Markets
Target end markets include patients, physicians, advocacy groups, and third-party payors in the rare disease space, contingent on regulatory approval of nomlabofusp. No commercial customers as of FY2025.
Geographic Exposure
Primarily United States-based operations, with regulatory and data privacy obligations noted in the European Union, United Kingdom, Brazil, and China in the context of clinical trial data handling.
Financial Snapshot
Loading...
